Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of MB07133 in unresectable advanced primary liver cancer
CTR20200165Phase 2Active
- Sponsor
- Xi'an Xintong Pharmaceutical
- Start
- Jul 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mbo7133 in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), Hepatocholangiocarcinoma (HCC-CC), sponsored by Xi'an Xintong Pharmaceutical. Started Jul 2020; status: active.
02
Drugs
mbo7133
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)Hepatocholangiocarcinoma (HCC-CC)
Beyond the preview
Go deeper on CTR20200165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200165.